BeOne Medicines Ltd. (ONC) Unveils Promising Breast Cancer Therapies at ASCO 2025

We recently published 11 Best Cancer Stocks to Buy Right Now. BeOne Medicines Ltd. stands seventh among the best cancer stocks.

BeOne Medicines Ltd. (NASDAQ:ONC) is a global oncology company advancing innovative treatments for solid tumors and blood cancers.

At the 2025 American Society of Clinical Oncology (ASCO) meeting, the company presented promising early-phase results for two novel breast cancer therapies. BG-C9074, an antibody-drug conjugate targeting the B7-H4 protein in breast and gynecologic cancers, delivers a potent topoisomerase I inhibitor directly to tumor cells. BG-68501, a cyclin-dependent kinase-2 inhibitor, is being developed for HR+/HER2- breast cancer patients who previously received CDK4/6 inhibitors. Both candidates reflect BeOne Medicines Ltd. (NASDAQ:ONC)’s targeted, biology-driven approach to breast cancer innovation.

In hematology, the business continues to expand BRUKINSA, its BTK inhibitor with proven efficacy in chronic lymphocytic leukemia (CLL) and other blood cancers. With its expanding pipeline and progress across multiple Phase 3 trials, the company is increasingly viewed as one of the best cancer stocks for investors seeking exposure to innovative therapies in both solid tumors and hematology.

Strategically, BeOne Medicines Ltd. (NASDAQ:ONC) recently redomiciled to Switzerland, strengthening its global footprint and positioning itself for broader international oncology leadership. With a growing pipeline and established therapies, the company is focused on delivering transformative treatments to address unmet needs in oncology worldwide.

While we acknowledge the potential of ONC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.